RecruitingNot ApplicableNCT05639413

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

A Study to Collect Patients, Medical, and Biological Data From Patients Being Treated for Metastatic Colorectal Cancer With a Specific Genetic Mutation: BRAFV600E

Sponsor

UNICANCER

Enrollment

400 participants

Start Date

Jul 24, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Colorectal Cancer BRAF V600E Mutation Positive

Summary

The study will be conducted in patients with metastatic colorectal cancer (mCRC) harboring a BRAFV600E mutation, to collect clinical data and biological samples to be used for research but also to gather real-world clinical data concerning the treatments and the survival outcomes in patients with this pathology.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is following patients with a specific type of advanced colorectal cancer (called BRAFV600E-mutated metastatic colorectal cancer) to better understand how the disease behaves over time and how it responds to treatment. It is an observational study — meaning doctors collect information but do not assign a specific treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with BRAFV600E-mutated metastatic colorectal cancer, confirmed by a tissue test - You are either treatment-naive (not yet had chemo for metastatic disease) or have started first-line chemotherapy - A tissue sample from your tumor is available for biological testing - Your cancer's mismatch repair (MMR) status has been or is being tested **You may NOT be eligible if...** - You only have a fine-needle aspiration biopsy and no solid tissue sample - You have already received encorafenib-cetuximab treatment - You are unable or unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCollection of blood samples

A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.

Locations(45)

Centre Hospitalier D'Avignon

Avignon, France

Centre Hospitalier de Bayeux

Bayeux, France

Chu Simone Veil

Beauvais, France

Institut Bergonie

Bordeaux, France

CH Fleyriat

Bourg-en-Bresse, France

Ch de Cahors

Cahors, France

CH Dr TECHER

Calais, France

Infirmerie Protestante de Lyon

Caluire-et-Cuire, France

Chu Estaing de Clermont-Ferrand

Clermont-Ferrand, France

GHPSO

Creil, France

Aphp - Hopital Henri Mondor

Créteil, France

Groupe Hospitalier Mutualiste de Grenoble

Grenoble, France

Chu de Grenoble Alpes - Hopital Michallon

La Tronche, France

CH Louis Pasteur

Le Coudray, France

Groupe Hospitalier Emile Roux

Le Puy-en-Velay, France

Hopital Franco-Britannique

Levallois-Perret, France

Chu Dupuytren

Limoges, France

Centre Leon Berard

Lyon, France

Hôpital privé Jean Mermoz

Lyon, France

Hopital de La Timone

Marseille, France

Intitut Paoli Calmettes

Marseille, France

Grand Hopital de L'Est Francilien - Site de Meaux

Meaux, France

Centre Antoine Lacassagne

Nice, France

CHR d'Orléans

Orléans, France

Aphp - Hopital Saint Louis

Paris, France

Hopital Saint Antoine

Paris, France

Aphp - Hopital Bichat

Paris, France

Aphp - La Pitie Salpetriere

Paris, France

Institut Mutualiste Montsouris

Paris, France

Gh Diaconesses Croix Saint Simon

Paris, France

Hopital Europeen Georges Pompidou

Paris, France

Ch Perpignan

Perpignan, France

Chu Poitiers

Poitiers, France

Chu de Reims

Reims, France

Chu Rennes Pontchaillou

Rennes, France

Chu de Rouen

Rouen, France

Hôpital Privé de la Loire

Saint-Etienne, France

Hnia Begin

Saint-Mandé, France

Ch de Saint Malo

St-Malo, France

Centre Paul Strauss

Strasbourg, France

Hnia Saint Anne

Toulon, France

Chu de Tours

Tours, France

Chru de Nancy

Vandœuvre-lès-Nancy, France

Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, France

Centre d'Oncologie Saint Yves

Vannes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05639413

Related Trials

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT061494811 location

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT011741211 location

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT0492922376 locations

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

NCT075597601 location

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649286 locations